First R&D Leadership Summit in San Francisco for Emerging Biotechs Announced by the Conference Forum

Share Article

R&D leaders have a new conference addressing the unique needs of emerging biotech drug development where business meets clinical trials in a resource constraint environment.

News Image
We are pleased to bring the first R&D Biotech Leadership event for a highly specialized population of people responsible for developing some of the most exciting therapeutics in a risk-adverse environment

The Conference Forum has announced the first R&D Biotech Leadership Summit to take place November 14-15 at the Marines’ Memorial Club in San Francisco. R&D emerging biotech leaders now have a conference that addresses innovation to advance clinical trials, creating and capturing value, managing growing pains and best practices for financing and exiting.

Former global head of innovation at Johnson & Johnson, Diego Miralles, MD, now CEO at Adaptive Therapeutics opens the lineup of keynotes on building impactful therapeutic programs. Immuno-oncology leader, Mark Frohlich, MD, EVP, Juno Therapeutics keynotes on going from 30 to 300 Employees. Additional keynote on Disrupting 21st Century Drug Development is delivered by digital clinical trial guru, Donald Jones, Chief Digital Officer, Scripps Translational Science Institute. The conference features CEO perspectives on R&D leadership in the current market, prioritizing R&D dollars and strategies for selecting and managing service providers for your organization. The program agenda also includes sessions on decision-making, regulatory best practices along and business development strategies.

“We are pleased to bring the first R&D Biotech Leadership event for a highly specialized population of people responsible for developing some of the most exciting therapeutics in a risk-adverse environment,” said Kate Woda, R&D Biotech Leadership Summit Director.

Co-chaired by Chris O’Brien, MD, Neurocrine Bioscience and Pamela Palmer, MD, PhD, AcelRX Pharmaceuticals, the conference is responsible for addressing critical issues impacting R&D executives in small and emerging biotechs.

2016 Confirmed Speakers:
Murray Aitken, MBA,SVP & Executive Director, IMS Institute for Health Informatics
Sunil Agarwal, MD, CMO, Ultragenyx Pharma
Lee Allen MD, PhD, CMO, Argos Therapeutics
Mark Bagarazzi, MD, CMO, Inovio
Jeffrey Bartlett, PhD, SVP R&D / CSO, Calimmune
Deirdre BeVard, VP, Development Operations, Nektar Therapeutics
James "Jim" Bolognese, Senior Director, Strategic Consulting, Cytel
Laurie Burke, Rph, MPH, Former Director, Study Endpoints and Labeling Development (SEALD), ONDIO, CDER / Founder, FDA/Lora Group
Pablo Cagnoni, MD, Managing Director / President & CEO, MPM Capital / Tizona Therapeutics
Anne-Marie Duliege, MD, MS, EVP, CMO, Rigel Pharmaceuticals Inc.
Mark Frohlich, MD, EVP, Development & Portfolio Strategy, Juno Therapeutics
Adam Hanina, CEO, AiCures
Donald Jones, MBA, Chief Digital Officer, Scripps Translational Science Institute
Thomas Lonngren, PhD (hc), MRPharmS, FRCP, Former Head / Strategic Advisor, EMA / NDA Group
Diego Miralles, MD, President, Adaptive Therapeutics
Susan Molineaux, PhD, Founder, President and CEO, Calithera Biosciences
Samuel Nussbaum, MD, Former EVP, Clinical Health Policy and CMO / Strategic Advisor, Anthem / Epstein Becker Green
Chris O'Brien, MD, CMO Neurocrine Biosciences
Pamela Palmer, MD, PhD, CMO & Co-founder, AcelRX Pharmaceuticals
Suyash Prasad, MD, SVP & CMO, Audentes Therapeutics
Sara Radcliffe, President & CEO, California Life Sciences Association
Camille Samuels, MBA, Partner, Venrock
Mark Simon, MBA, Managing Partner, Torreya Partners
Jamey Skillings, MD, Former SVP & CMO, Tocogen
Komathi Stem, MS, Former Strategic Innovation Leader / Chief Operating Officer    Genentech/Roche / Science 37
Barbara Troupin, MD,    Former SVP, CMO, Apricus Biosciences
Mark Weinberg, MD, MBA, CMO and Managing Director, Halloran Consulting Group
John Varian, CEO, Xoma

History of R&D Biotech Leadership Summit
Formerly the annual Chief Medical Officer West conference, the R&D Biotech Leadership Summit was introduced to now include those executives in small and emerging biotech who are responsible for R&D functions and is dedicated to accomplish two goals:

  • To bring together senior level R&D executives to address the unique challenges associated with directing all R&D functions with limited resources, while raising capital and strategizing for appropriate exits.
  • To create a network of R&D executives from emerging biotech/pharma companies to share ideas, solutions and support.

For more details on the agenda and presenters, please visit:

About the Conference Forum
The Conference Forum develops specialized events for professionals in the life science and healthcare industries. We currently offer conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists, patient advocates and FDA executives. The Conference Forum mission is to create the best content, exchange ideas and provide quality networking to help move therapeutics to patients faster.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jessica Rothenberg
Follow us on
Visit website